Fondation Merieux 2017
CEPI
Almost basking about their list being more inclusive, more emergent viruses based.
https://t.co/J5FDe6W986
Fondation Merieux 2017
Narrative: "Look, what ZIKA has done to your populace. Nasty ZIKA."
How much of that ZIKA damage was actually related to a virus? Was there a computer guy, who had invested in mosquitos as a vector?
https://t.co/J5FDe6W986
Fondation Merieux 2017
What is the advanges of a programme like CEPI.
And for who?
Let me translate: They want a coordinated vaccine production, with only one strong production pipeline, and solidly regulated pathsways.
Provide the incentives for big pharma.
They've made it.
Vision - look at nasty ZIKA, you surely do not want that
Mission - get the pipeline going of (only) the big ones
Scope - the anti-cancer platforms with their DNA, mRNA basis fit perfectly. They so far do not sell very well, but they could be recycled.
Correct me, if I am wrong.
How to create your own market and exclude competitors right from the start.
Start even before the 'incident' - which will give you more advantage of your competitors.
'Booster' it. ZIKA, MERS?
Get people used to the forced vaccine narrative with measles?
Correct me,if I am wrong
Fondation Merieux 2017
CEPI narrative presentation
They show a remarkable interest in MERS
A 'pipeline booster'?
MERS in Korea
Why not try it out and create some interesting PR pictures at the same time?
https://t.co/hrCU2xVi3U
Fondation Merieux 2017
CEPI sales presentation
They were envisaging 3 different vaccines:
- quick response but not long lasting immunity
- long lasting immunity vaccines for specific groups of people
- vaccinating animals because of the animal reservoir.
ALL the markets
Nicola Bidoli, let us just pretend, you were still around here.
MERS Vx trial run?
Can you spot Baculovirus, production in mice, sf9, VLP, full length S trimers here.
We can already spot Novavax here, doing a trial run.
I am sure, you would spot more.
https://t.co/J5FDe6W986
MERS Vx trial run
More good old known here
Nice sandbox toy area. Look who is all at play.
German PEI in it as well with a Measles Vector.
Drosten with a DZIF minimal vector approach.
And also some recombinant.
The REAL GERM GAMES
Sandbox. Give it a try.
Oh, and look
GeneOne Inovio is on board as well sailing the sandbox of a fading vx platform booster outbreak.
They knew what to look for - what makes a good immune response for a vaccine:
Antibodies and
Induction of strong T-cell immune responses
• Antigen specific CD4+ and CD8+
• Multiple epitopes recognized across length of S protein
Have they forgotten about cellular response now?
Human Trial MERS vax sandbox arena
They were even then working on a multi jab approach. Here they were looking at three jabs.
Dose 1: week 1
Dose 2: week 5
Dose 3: week 14
1 month, 3 months
75 people
Fondation Merieux
"MERS-CoV vaccine landscape will change
dramatically in near future"
Yes, mRNA was in the pipeline. Still restricted by the toxicity of the LNP (Moderna first major pipeline). Bancel moved on to Moderna.
https://t.co/hsnNHePvRw
Giuseppe Ciaramella | Chief Scientific Officer
Valera - fully owned by Moderna
Has certainly brought the LNP development further
https://t.co/usCgynv5wU
A sight aside on
MODERNA LNP and the 'competitive landscape of mRNA vaccines'
Patents 069 435
#Patents #435 & #069
https://t.co/iAka69L1RO
A sight aside on
MODERNA LNP and the 'competitive landscape of mRNA vaccines'
Part II
Patents 069 435
#Patents #435 & #069
https://t.co/68QlxcsbjH
Another just aside
MODERNA patents
Patents 069 435
#Patents #435 & #069
Lawyers
https://t.co/sLMtQwd0i8 https://t.co/8dCSyAKJgd Property Dispute
https://t.co/saorrrZ8E1 Arbutus '19 article
https://t.co/d1B0IbdWBm Arbutus '20 article
https://t.co/qbWjWBXY1l
Back to the sandbox MERS approach
They knew what they let themselves in for in 2017
Not so long ago. Has really that much changed since then - or, is there a lot of hot needle knitting involved?
https://t.co/J5FDe6W986
Merieux and the IVI vaccine institute